The Q3 exceeded expectations, driven by strong momentum in Oncology and CVRM, and a healthy contribution from Alexion (rare diseases), thereby more than compensating for the decline in COVID-19 vaccine sales – which was never going to be a game-changer. Moreover, aside from top-line growth, profitability was aided by lower R&D expenses. Consequently, the 2022 EPS guidance was upgraded. Overall, a strong portfolio, including a relatively young and high-potential oncology franchise supported by ot ....
11 Nov 2022
Oncology-led momentum sustained in Q3 + guidance upgraded
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Oncology-led momentum sustained in Q3 + guidance upgraded
AstraZeneca PLC (AZN:LON) | 10,953 3505 0.3% | Mkt Cap: 169,797m
- Published:
11 Nov 2022 -
Author:
Abhishek Raval -
Pages:
4
The Q3 exceeded expectations, driven by strong momentum in Oncology and CVRM, and a healthy contribution from Alexion (rare diseases), thereby more than compensating for the decline in COVID-19 vaccine sales – which was never going to be a game-changer. Moreover, aside from top-line growth, profitability was aided by lower R&D expenses. Consequently, the 2022 EPS guidance was upgraded. Overall, a strong portfolio, including a relatively young and high-potential oncology franchise supported by ot ....